GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The company has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.
Follow-Up Questions
Globeimmune Inc 'in CEO'su kimdir?
Dr. Timothy Rodell 2003 'den beri şirketle birlikte olan Globeimmune Inc 'in President 'ıdır.
GBIM hissesinin fiyat performansı nasıl?
GBIM 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Globeimmune Inc için ana iş temaları veya sektörler nelerdir?
Globeimmune Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Globeimmune Inc 'in piyasa değerlemesi nedir?
Globeimmune Inc 'in mevcut piyasa değerlemesi $0 'dir
